Loading…
Suspicious Order Identification Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Suspicious Order Identification Act of 2019 This bill requires the Drug Enforcement Administration to implement a program that requires real-time reporting of every sale, delivery, or disposal of any controlled substance (i.e., substances regulated under federal law because of their potential for dependence and addiction).The bill also establishes a Suspicious Order Monitoring Task Force to make recommendations regarding the program. Until the program is operational, the bill also increases the frequency of current reporting requirements.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2020 · fourth_quarter · Pharmacy
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Pharmacy
Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (H.R. 3878) Debarment Act (H.R. 4806) Ensuring Compliance Against Drug Diversion (H.R. 4812) Suspicious Order Identification Act of 2019 (S. 2686, H.R. 4814)
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Pharmacy
Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Debarment Act (HR 4806) Ensuring Compliance Against Drug Diversion (HR 4812) Suspicious Order Identification Act of 2019 (S. 2686, HR 4814)
Client expense: $285,896 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Pharmacy
S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019; H.R. 4812-Ensuring Compliance Against Drug Diversion Act of 2019; H.R. 4806-Tthe Debarment Enforcement of Bad Actor Registrants Act of 2019; H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020; HR 7574-Strengthening America's Strategic National Stockpile Act of 2020.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Pharmacy
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Pharmacy
Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Debarment Act (HR 4806) Ensuring Compliance Against Drug Diversion (HR 4812) Suspicious Order Identification Act of 2019 (S. 2686, HR 4814)
Client expense: $336,505 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Pharmacy
S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019; H.R. 4812-Ensuring Compliance Against Drug Diversion Act of 2019; H.R. 4806-Tthe Debarment Enforcement of Bad Actor Registrants Act of 2019; H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020; HR 7574-Strengthening America's Strategic National Stockpile Act of 2020.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Pharmacy
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Pharmacy
Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019, H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020);implementation of Public Law 113-54 (DSCSA).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Pharmacy
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Pharmacy
Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting (S. 3070, S. 2686, HR 4814) Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Preventing Pill Mills Through Data Sharing Act - S. 3070 Suspicious Order Identification Act of 2019 - S. 2686 Suspicious Order Identification Act of 2019 - HR 4814
Client expense: $313,210 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Pharmacy
Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019); importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Medicare/Medicaid
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
Issues related to ARCOS data and suspicious order record requirements and reporting: S.3070-Preventing Pill Mills Through Data Sharing Act; S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019;importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting (S. 3070, S. 2686, HR 4814) Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Preventing Pill Mills Through Data Sharing Act - S. 3070 Suspicious Order Identification Act of 2019 - S. 2686 Suspicious Order Identification Act of 2019 - HR 4814
Client expense: $314,777 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE